肾素-血管紧张素-醛固酮系统（RAAS）抑制与过氧化物酶体增殖物激活受体γ（PPAR-γ）激动在糖尿病预防中的作用：雷米普利与罗格列酮降低糖尿病风险评估（DREAM）试验 - Suppr

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

作者信息

McFarlane Samy I, Provilus Alfrede, Shin John J

机构信息

Division of Endocrinology, Diabetes and Hypertension, State University of New York Health Science Center and Kings County Hospital Center, Brooklyn, NY 11203, USA.

出版信息

J Cardiometab Syndr. 2007 Spring;2(2):149-50. doi: 10.1111/j.1559-4564.2007.06663.x.

DOI:10.1111/j.1559-4564.2007.06663.x

PMID:17684471

Abstract

摘要

相似文献

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

J Cardiometab Syndr. 2007 Spring;2(2):149-50. doi: 10.1111/j.1559-4564.2007.06663.x.

[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].

Rev Med Liege. 2006 Oct;61(10):728-32.

[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].

Internist (Berl). 2007 Oct;48(10):1173-6. doi: 10.1007/s00108-007-1932-8.

[Three studies in type 2 diabetes: DREAM the wash-out results].

Ann Endocrinol (Paris). 2007 Jun;68 Suppl 1:36-8. doi: 10.1016/s0003-4266(07)80009-6.

Diabetes prevention: still no effective drugs.

Prescrire Int. 2007 Dec;16(92):258.

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11.

Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.

Ann Intern Med. 2007 Mar 20;146(6):461-3. doi: 10.7326/0003-4819-146-6-200703200-00015.

[Experiences of the DREAM trial].

Orv Hetil. 2006 Dec 31;147(52):2523-6.

[The DREAM of diabetes prevention].

Rev Med Suisse. 2007 Jan 17;3(94):132, 134-6.

Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Diabet Med. 2010 Nov;27(11):1226-32. doi: 10.1111/j.1464-5491.2010.03064.x.

引用本文的文献

Management of arterial hypertension in obese patients.

Curr Hypertens Rep. 2007 Dec;9(6):491-7. doi: 10.1007/s11906-007-0090-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

J Cardiometab Syndr. 2007 Spring;2(2):149-50. doi: 10.1111/j.1559-4564.2007.06663.x.

[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].

Rev Med Liege. 2006 Oct;61(10):728-32.

[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].

Internist (Berl). 2007 Oct;48(10):1173-6. doi: 10.1007/s00108-007-1932-8.

[Three studies in type 2 diabetes: DREAM the wash-out results].

Ann Endocrinol (Paris). 2007 Jun;68 Suppl 1:36-8. doi: 10.1016/s0003-4266(07)80009-6.

Diabetes prevention: still no effective drugs.

Prescrire Int. 2007 Dec;16(92):258.

Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11.

Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.

Ann Intern Med. 2007 Mar 20;146(6):461-3. doi: 10.7326/0003-4819-146-6-200703200-00015.

[Experiences of the DREAM trial].

Orv Hetil. 2006 Dec 31;147(52):2523-6.

[The DREAM of diabetes prevention].

Rev Med Suisse. 2007 Jan 17;3(94):132, 134-6.

Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Diabet Med. 2010 Nov;27(11):1226-32. doi: 10.1111/j.1464-5491.2010.03064.x.

引用本文的文献

Management of arterial hypertension in obese patients.

Curr Hypertens Rep. 2007 Dec;9(6):491-7. doi: 10.1007/s11906-007-0090-7.

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

作者信息

McFarlane Samy I, Provilus Alfrede, Shin John J

机构信息

Division of Endocrinology, Diabetes and Hypertension, State University of New York Health Science Center and Kings County Hospital Center, Brooklyn, NY 11203, USA.

出版信息

J Cardiometab Syndr. 2007 Spring;2(2):149-50. doi: 10.1111/j.1559-4564.2007.06663.x.

DOI:10.1111/j.1559-4564.2007.06663.x

PMID:17684471

Abstract

摘要

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

作者信息

机构信息

出版信息